"We also expect to publish interim efficacy data of Sputnik V clinical trials in November", Dmitriev said in a press release.
He went on to say that the Russian Direct Investment Fund (RDIF) welcomed the news of the successful trials of Pfizer's vaccine.
"Our strong belief is that the world needs a large portfolio of successful vaccines based on different platforms", he said.
The statement comes after the RDIF and the Gamaleya Research Institute of Epidemiology and Microbiology announced readiness to launch a new social media campaign to raise awareness and provide the latest information on developments regarding the Sputnik V vaccine.
Earlier today, the federal response centre said that Russia had registered a new single-day record of 21,798 COVID-19 cases, up from 20,498 yesterday, bringing the total to 1,796,132.
Sputnik V, which was developed by the Gamaleya centre and produced in cooperation with the RDIF, became the world's first registered vaccine against COVID-19 when it was registered by the Russian Ministry of Health on 11 August.
Stage three clinical trials of the vaccine are underway in Russia, and trials have to date also been announced in the United Arab Emirates, India, Venezuela, and Belarus.